


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app42.us.archive.org';v.server_ms=331;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180609222134im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180609222134im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180609222134im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180609222134im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180609222134/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180609222134im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180609222134cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180609222134js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180609222134if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180609222134/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180609222134if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180609222134/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180609222134/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180609222134/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180609222134/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180609222134/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180609222134/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180609222134/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180609222134/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180609222134/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180609222134/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180609222134/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180609222134/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180609222134/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180609222134/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180609222134/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180609222134/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180609222134/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180609222134/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180609222134/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180609222134/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:009998</li>
            <li>2013 Nov
            </li>            
                                </ul>
        <div>
                <h1>BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Guideline_Developer_String=British%20Society%20for%20Haematology%20Guidelines&amp;fLockTerm=British%2BSociety%2Bfor%2BHaematology%2BGuidelines">British Society for Haematology Guidelines</a></li>
                        <li>   
                                <a id="1851" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Guideline_Developer_String=British%20Society%20of%20Blood%20and%20Marrow%20Transplantation&amp;fLockTerm=British%2BSociety%2Bof%2BBlood%2Band%2BMarrow%2BTransplantation">British Society of Blood and Marrow Transplantation</a></li>
                        <li>   
                                <a id="2347" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013 Nov;163(4):444-57. [99 references] <a href="https://web.archive.org/web/20180609222134/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24102514" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180609222134/https://www.guideline.gov/Home/Disclaimer?id=47069&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fonlinelibrary.wiley.com%252fdoi%252f10.1111%252fbjh.12558%252ffull">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Adolescent%20%2813%20to%2018%20years%29&amp;fLockTerm=Adolescent%2B%2813%2Bto%2B18%2Byears%29">Adolescent (13 to 18 years)</a></li>                      
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Child%20%282%20to%2012%20years%29&amp;fLockTerm=Child%2B%282%2Bto%2B12%2Byears%29">Child (2 to 12 years)</a></li>                      
                        <li><a href="/web/20180609222134/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180609222134/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0010337&amp;fLockTerm=Critical+Care">Critical Care</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0016018&amp;fLockTerm=Fibrinolytic+Agents">Fibrinolytic Agents</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0472699&amp;fLockTerm=Hematopoietic+Stem+Cell+Transplantation">Hematopoietic Stem Cell Transplantation</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0019156&amp;fLockTerm=Hepatic+Veno-Occlusive+Disease">Hepatic Veno-Occlusive Disease</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0023911&amp;fLockTerm=Liver+Transplantation">Liver Transplantation</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0025815&amp;fLockTerm=Methylprednisolone">Methylprednisolone</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0032177&amp;fLockTerm=Platelet+Aggregation+Inhibitors">Platelet Aggregation Inhibitors</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0032468&amp;fLockTerm=Polydeoxyribonucleotides">Polydeoxyribonucleotides</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0339897&amp;fLockTerm=Portasystemic+Shunt%2c+Transjugular+Intrahepatic">Portasystemic Shunt, Transjugular Intrahepatic</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0086930&amp;fLockTerm=Risk+Assessment">Risk Assessment</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0035648&amp;fLockTerm=Risk+Factors">Risk Factors</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0042105&amp;fLockTerm=Ursodeoxycholic+Acid">Ursodeoxycholic Acid</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MSH_CUI=C0043064&amp;fLockTerm=Water-Electrolyte+Balance">Water-Electrolyte Balance</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0193388&amp;fLockTerm=Biopsy+of+liver+(procedure)">Biopsy of liver (procedure)</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0010337&amp;fLockTerm=Care+of+intensive+care+unit+patient">Care of intensive care unit patient</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0057257&amp;fLockTerm=defibrotide">defibrotide</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0016018&amp;fLockTerm=Fibrinolytic+Agents">Fibrinolytic Agents</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0019156&amp;fLockTerm=Hepatic+Veno-Occlusive+Disease">Hepatic Veno-Occlusive Disease</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0032177&amp;fLockTerm=Platelet+Aggregation+Inhibitors">Platelet Aggregation Inhibitors</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0086930&amp;fLockTerm=Risk+Assessment">Risk Assessment</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0035648&amp;fLockTerm=risk+factors">risk factors</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0542331&amp;fLockTerm=Shunt+Device">Shunt Device</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0339897&amp;fLockTerm=Transjugular+intrahepatic+portosystemic+shunt+procedure">Transjugular intrahepatic portosystemic shunt procedure</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0023911&amp;fLockTerm=Transplantation+of+liver">Transplantation of liver</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0042105&amp;fLockTerm=Ursodiol">Ursodiol</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0948441&amp;fLockTerm=Venoocclusive+disease">Venoocclusive disease</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C1842297&amp;fLockTerm=VENOOCCLUSIVE+DISEASE+AFTER+BONE+MARROW+TRANSPLANTATION%2c+SUSCEPTIBILITY+TO">VENOOCCLUSIVE DISEASE AFTER BONE MARROW TRANSPLANTATION, SUSCEPTIBILITY TO</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_MTH_CUI=C0043064&amp;fLockTerm=Water-Electrolyte+Balance">Water-Electrolyte Balance</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0005558&amp;fLockTerm=biopsies">biopsies</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0057257&amp;fLockTerm=defibrotide">defibrotide</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0023911&amp;fLockTerm=liver+transplantation">liver transplantation</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0025815&amp;fLockTerm=methylprednisolone">methylprednisolone</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0041618&amp;fLockTerm=ultrasonography">ultrasonography</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0042105&amp;fLockTerm=ursodiol">ursodiol</a>
, <a href="/web/20180609222134/https://www.guideline.gov/search?f_PDQ_CUI=C0948441&amp;fLockTerm=veno-occlusive+disease">veno-occlusive disease</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
 (129314006), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
 (86273004), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0193388&amp;fLockTerm=Biopsy+of+liver">Biopsy of liver</a>
 (86259008), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010337&amp;fLockTerm=Care+of+intensive+care+unit+patient">Care of intensive care unit patient</a>
 (133903000), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0057257&amp;fLockTerm=Defibrotide">Defibrotide</a>
 (441573002), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0057257&amp;fLockTerm=Defibrotide">Defibrotide</a>
 (442263003), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016284&amp;fLockTerm=Fluid+balance">Fluid balance</a>
 (251856003), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0472699&amp;fLockTerm=Hemopoietic+stem+cell+transplant">Hemopoietic stem cell transplant</a>
 (234336002), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025815&amp;fLockTerm=Methylprednisolone">Methylprednisolone</a>
 (116593003), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025815&amp;fLockTerm=Methylprednisolone">Methylprednisolone</a>
 (27242001), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0086930&amp;fLockTerm=Risk+assessment">Risk assessment</a>
 (225338004), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0035648&amp;fLockTerm=Risk+factor">Risk factor</a>
 (80943009), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0542331&amp;fLockTerm=Shunt">Shunt</a>
 (257351008), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016018&amp;fLockTerm=Thrombolytic">Thrombolytic</a>
 (303960004), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016018&amp;fLockTerm=Thrombolytic">Thrombolytic</a>
 (372742009), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0339897&amp;fLockTerm=Transjugular+intrahepatic+portosystemic+shunt">Transjugular intrahepatic portosystemic shunt</a>
 (233445008), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0023911&amp;fLockTerm=Transplantation+of+liver">Transplantation of liver</a>
 (18027006), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
 (16310003), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
 (278292003), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&amp;fLockTerm=Ultrasonography">Ultrasonography</a>
 (359659005), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042105&amp;fLockTerm=Ursodiol">Ursodiol</a>
 (108669000), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042105&amp;fLockTerm=Ursodiol">Ursodiol</a>
 (41143004), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0019156&amp;fLockTerm=Veno-occlusive+disease+of+the+liver">Veno-occlusive disease of the liver</a>
 (65617004), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0948441&amp;fLockTerm=Venous+occlusion">Venous occlusion</a>
 (307221007), <a href="/web/20180609222134/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0043064&amp;fLockTerm=Water-electrolyte+balance">Water-electrolyte balance</a>
 (16379007)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SPN</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_SPN_CUI=C0302622&amp;fLockTerm=SYSTEM%2c+IMAGING%2c+PULSED+DOPPLER%2c+ULTRASONIC">SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180609222134/https://www.guideline.gov/search?f_UMD_CUI=C0302622&amp;fLockTerm=Scanning+Systems%2c+Ultrasonic">Scanning Systems, Ultrasonic</a>
 (14-278), <a href="/web/20180609222134/https://www.guideline.gov/search?f_UMD_CUI=C0542331&amp;fLockTerm=Shunts">Shunts</a>
 (13-585)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#430" class="section-mark">Contraindications</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/downloadcontent/ngc-9998?contentType=pdf" class="pdf">.PDF 80.4 kb</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/downloadcontent/ngc-9998?contentType=word" class="word">Word Document 283.9 kb</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/downloadcontent/ngc-9998?contentType=xml" class="xml">.XML 33.6 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180609222134/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180609222134/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180609222134/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180609222134/mailto:/?Subject=AHRQ: BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.&amp;body=https://www.guideline.gov/summaries/summary/47069/bcshbsbmt-guideline-diagnosis-and-management-of-venoocclusive-disease-sinusoidal-obstruction-syndrome-following-haematopoietic-stem-cell-transplantation" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Sep 17. [cited 2018 Jun 09]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=enw">EndNote</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=txt">Medlars</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=ris">ProCite</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069">RefWorks</a></li>
                            <li><a href="/web/20180609222134/https://www.guideline.gov/summaries/citedownload/47069?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47069" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions for the quality of the evidence (<strong>A&ndash;C</strong>) and strength of recommendations (strong [grade <strong>1</strong>], weak [grade <strong>2</strong>]) are given at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Diagnosis</span></strong></p>
<p><strong>Diagnostic Techniques</strong></p>
<ul style="list-style-type: disc;">
    <li>It is recommended that the diagnosis of veno-occlusive disease (VOD) (sinusoidal obstruction syndrome) be based primarily on established clinical criteria (modified Seattle or Baltimore criteria) (<strong>1A</strong>). </li>
    <li>Ultrasound imaging may be helpful in the exclusion of other disorders in patients with suspected VOD (sinusoidal obstruction syndrome) (<strong>1C</strong>). </li>
    <li>It is recommended that liver biopsy be reserved for patients in whom the diagnosis of VOD (sinusoidal obstruction syndrome) is unclear and there is a need to exclude other diagnoses (<strong>1C</strong>). </li>
    <li>It is recommended that liver biopsies are undertaken using the transjugular approach in order to reduce the risks associated with the procedure (<strong>1C</strong>). </li>
    <li>It is suggested that the role of plasminogen activator inhibitor-1 levels remains an area for further research but that these levels do not form part of the routine diagnostic work-up for VOD (sinusoidal obstruction syndrome) at present (<strong>2C</strong>). </li>
</ul>
<p><strong><span style="text-decoration: underline;">Prevention of VOD</span></strong></p>
<ul style="list-style-type: disc;">
    <li>It is recommended that patients are assessed for risk factors for VOD (sinusoidal obstruction syndrome) and that these risk factors are addressed prior to haematopoietic stem cell transplantation (<strong>1A</strong>). </li>
    <li>Defibrotide is recommended at a dose of 6.25 milligrams/kg intravenously 4 times daily for the prevention of VOD (sinusoidal obstruction syndrome) in children undergoing allogeneic stem cell transplantation with the following risk factors: pre-existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleukodystrophy or osteopetrosis (<strong>1A</strong>). </li>
    <li>Defibrotide is suggested at a dose of 6.25 milligrams/kg intravenously 4 times daily for the prevention of VOD (sinusoidal obstruction syndrome) in adults undergoing allogeneic stem cell transplantation with the following risk factors: pre-existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleukodystrophy or osteopetrosis (<strong>2B</strong>). </li>
    <li>Prostaglandin E1 is not recommended in the prophylaxis of VOD (sinusoidal obstruction syndrome) due to lack of efficacy and toxicity (<strong>1B</strong>). </li>
    <li>Pentoxifylline is not recommended in the prophylaxis of VOD (sinusoidal obstruction syndrome) due to lack of efficacy (<strong>1A</strong>). </li>
    <li>Ursodeoxycholic acid is suggested for use in the prophylaxis of VOD (sinusoidal obstruction syndrome) (<strong>2C</strong>). </li>
    <li>Heparin (unfractionated and low molecular weight) is not suggested for use in the prophylaxis of VOD (sinusoidal obstruction syndrome) due to the risk of increased toxicity (<strong>2B</strong>). </li>
    <li>Anti-thrombin is not suggested for the prophylaxis of VOD (sinusoidal obstruction syndrome) due to lack of efficacy (<strong>2B</strong>). </li>
</ul>
<p><strong><span style="text-decoration: underline;">Treatment of VOD</span></strong></p>
<ul style="list-style-type: disc;">
    <li>Defibrotide is recommended in the treatment of VOD (sinusoidal obstruction syndrome) in adults and children (<strong>1B</strong>). </li>
    <li>Tissue plasminogen activator (TPA) is not recommended for use in the treatment of VOD (sinusoidal obstruction syndrome) due to the associated risk of haemorrhage (<strong>1B</strong>). </li>
    <li>N-acetylcysteine is not routinely recommended for use in the treatment of VOD due to lack of efficacy (<strong>1A</strong>). </li>
    <li>Methylprednisolone may be considered for use in the treatment of VOD with the appropriate caveats of caution regarding infection (<strong>2C</strong>). </li>
    <li>Judicious clinical care particularly in the management of fluid balance is recommended in the management of VOD (sinusoidal obstruction syndrome) (<strong>1C</strong>). </li>
    <li>Early discussion with critical care specialists and a specialist hepatology unit is recommended in the management of VOD (sinusoidal obstruction syndrome) and other treatment options including transjugular intrahepatic portosystemic shunt (TIPS) or hepatic transplantation may be considered (<strong>1C</strong>). </li>
</ul>
<p><span style="text-decoration: underline;"><strong>Definitions</strong></span>:</p>
<p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong> Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong> Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong> Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.</p>
<p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Diagnosis</p>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Prevention</p>
                    <p>Risk Assessment</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Gastroenterology</p>
                    <p>Hematology</p>
                    <p>Internal Medicine</p>
                    <p>Pediatrics</p>
                    <p>Preventive Medicine</p>
                    <p>Surgery</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To provide recommendations for the diagnosis and management of veno-occlusive disease of the liver following haematopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Children and adults undergoing haematopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Diagnosis/Risk Assessment</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Use of established clinical criteria (modified Seattle or Baltimore criteria) for diagnosis </li>
    <li>Ultrasound </li>
    <li>Liver biopsy </li>
    <li>Assessment for risk factors </li>
</ol>
<p><strong>Prevention/Treatment/Management</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Defibrotide </li>
    <li>Ursodeoxycholic acid </li>
    <li>Methylprednisolone </li>
    <li>Judicious clinical (fluid balance) </li>
    <li>Discussion with critical care specialists </li>
    <li>Transjugular intrahepatic portosystemic shunt (TIPS) </li>
    <li>Hepatic transplantation </li>
</ol>
<p class="Note"><strong>Note</strong>: The following are not recommended: prostaglandin E1, pentoxifylline, heparin, and anti-thrombin for prophylaxis of veno-occlusive disease (VOD), and tissue plasminogen activator (TPA), N-acetylcysteine&nbsp;for treatment of VOD.</p></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Clinical, histopathologic, and imaging features of veno-occlusive disease (VOD) </li>
    <li>Risk factors associated with VOD </li>
    <li>Treatment-related toxicity and adverse events </li>
    <li>Efficacy of VOD prevention (e.g., measured by incidence of VOD, mortality) </li>
    <li>Efficacy of VOD treatment (e.g., measured by resolution of VOD, complete response rate, survival rate) </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>The production of these guidelines involved establishment of a working group comprising experts in the field of allogeneic transplantation followed by literature review to 15/2/2013. Medline was searched systematically for publications in English using the following key words: veno-occlusive disease and sinusoidal obstruction syndrome. The reports of major conferences were also reviewed using the same keywords.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Quality of Evidence</strong></p>
<p>The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.</p>
<p><strong>(A) High</strong> Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.</p>
<p><strong>(B) Moderate</strong> Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &ndash; wide confidence intervals or methodological flaws &ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose-response gradient).</p>
<p><strong>(C) Low</strong> Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series, or just opinion.</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence (see the "Rating Scheme for the Strength of the Evidence" field).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of veno-occlusive disease of the liver following haematopoietic stem cell transplantation.</p>
<p>The production of these guidelines involved the following steps:</p>
<ul style="list-style-type: disc;">
    <li>Development of key recommendations based on randomised, controlled trial evidence. Due to the paucity of randomised studies some recommendations are based on literature review and a consensus of expert opinion. </li>
    <li>The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) nomenclature was used to assess the strength of recommendations. The GRADE criteria are specified in the BCSH guideline pack and the GRADE working group website. See the "Rating Scheme for the Strength of the Recommendations" field. Further information is available from the following websites:
    <ul style="list-style-type: disc;">
        <li><a href="/web/20180609222134/https://www.guideline.gov/Home/Disclaimer?id=47069&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.bcshguidelines.com%2fBCSH_PROCESS%2f42_EVIDENCE_LEVELS_AND_GRADES_OF_RECOMMENDATION.html" title="BCSH Web site">http://www.bcshguidelines.com/BCSH_PROCESS/42_EVIDENCE_LEVELS_AND_GRADES_OF_RECOMMENDATION.html</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (accessed 28/6/2013) </li>
        <li><a href="/web/20180609222134/https://www.guideline.gov/Home/Disclaimer?id=47069&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.gradeworkinggroup.org%2findex.htm" title="GRADE Working Group Web site">http://www.gradeworkinggroup.org/index.htm</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (accessed 28/6/2013) </li>
    </ul>
    </li>
</ul></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Strength of Recommendations</strong></p>
<p><strong>Strong (grade 1)</strong>: Strong recommendations (grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as 'recommend'.</p>
<p><strong>Weak (grade 2)</strong>: Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as 'suggest'.</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The production of these guidelines involved the following steps:</p>
<ul style="list-style-type: disc;">
    <li>Review by the British Committee for Standards in Haematology (BCSH) committees, British Society of Blood and Marrow Transplantation (BSBMT) executive committee, and the UK Paediatric Bone Marrow Transplant Group </li>
    <li>Review by sounding board of the British Society for Haematology (BSH) and allogeneic transplant centres in the UK </li>
</ul></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>In a single arm phase II study of defibrotide, the main toxicities were haemorrhage in 18% and hypotension in 4% of patients with 2% of patients experiencing life-threatening haemorrhage.</p></div></p>

            </div>
                <h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Contraindications</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Prostaglandin E1 is not recommended in the prophylaxis of veno-occlusive disease (VOD) (sinusoidal obstruction syndrome) due to lack of efficacy and toxicity. </li>
    <li>Tissue plasminogen activator (TPA) is not recommended for use in the treatment of VOD (sinusoidal obstruction syndrome) due to the associated risk of haemorrhage. </li>
</ul></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology, nor the British Society of Blood and Marrow Transplantation nor the publishers accept any legal responsibility for the content of these guidelines. </li>
    <li>Defibrotide is an unlicensed drug and clinicians using this agent should be aware that its use does not have approval of regulatory authorities. The role of this agent is discussed in these guidelines for prophylaxis and treatment of veno-occlusive disease (sinusoidal obstruction syndrome) as there are no similar licensed agents available. </li>
    <li>The use of defibrotide in adults undergoing haematopoietic stem cell transplantation would be at the discretion of the treating physician as it is an unlicensed drug and, at present, the data available primarily relates to its use in children. </li>
</ul></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                    <p>Staying Healthy</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Patient-centeredness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013 Nov;163(4):444-57. [99 references] <a href="https://web.archive.org/web/20180609222134/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24102514" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Nov</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>British Society for Haematology Guidelines - Professional Association</p>
                    <p>British Society of Blood and Marrow Transplantation - Professional Association</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>British Committee for Standards in Haematology</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Authors</em>: Fiona L. Dignan, Department of Haematology, Central Manchester NHS Foundation Trust, Manchester; Robert F. Wynn, Royal Manchester Children's Hospital, Manchester; Nedim Hadzic, Paediatric Liver Service &amp; Institute of Liver Studies, King's College Hospital, London; John Karani, Department of Radiology, King's College Hospital, London; Alberto Quaglia, Department of Histopathology, King's College Hospital, London; Antonio Pagliuca, Department of Haematological Medicine, King's College Hospital, London; Paul Veys, Department of Bone Marrow Transplantation, Great Ormond Street Hospital, London; Michael N. Potter, Section of Haemato-oncology, The Royal Marsden NHS Foundation Trust, London</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>FLD, JK, AQ, NH, and PV have no conflicts of interest to declare. MNP, RFW, and AP have participated in an advisory board for Gentium. AP has received speaker's fees from Gentium.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: Available from the <a href="/web/20180609222134/https://www.guideline.gov/Home/Disclaimer?id=47069&amp;contentType=summary&amp;redirect=http%3a%2f%2fonlinelibrary.wiley.com%2fdoi%2f10.1111%2fbjh.12558%2ffull" title="British Journal of Haematology Web site">British Journal of Haematology Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180609222134im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the British Committee for Standards in Haematology; Email: <a href="https://web.archive.org/web/20180609222134/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on October 18, 2013.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: <a href="https://web.archive.org/web/20180609222134/mailto:bcsh@b-s-h.org.uk">bcsh@b-s-h.org.uk</a>.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180609222134/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180609222134/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180609222134/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011374</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180609222134/https://www.guideline.gov/summaries/summary/51296/crisis-intervention-for-adults-using-a-traumainformed-approach-initial-four-weeks-of-management-third-edition">Crisis intervention for adults using a trauma-informed approach: initial four weeks of management, third edition.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011371</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180609222134/https://www.guideline.gov/summaries/summary/51293/implementing-supervised-injection-services">Implementing supervised injection services.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011350</li>
            <li>2018 Feb 1</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180609222134/https://www.guideline.gov/summaries/summary/51272/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update">Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011349</li>
            <li>2017 Sep</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180609222134/https://www.guideline.gov/summaries/summary/51271/preventing-falls-and-reducing-injury-from-falls-fourth-edition">Preventing falls and reducing injury from falls, fourth edition.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011348</li>
            <li>2017</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180609222134/https://www.guideline.gov/summaries/summary/51270/occupational-therapy-practice-guidelines-for-cancer-rehabilitation-with-adults">Occupational therapy practice guidelines for cancer rehabilitation with adults.</a></p>
    </div>

    <a class="block-link" href="/web/20180609222134/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180609222134/https://www.guideline.gov/disclaimer?id=47069&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180609222134/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180609222134/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180609222134/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180609222134/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180609222134/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180609222134/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180609222134/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180609222134/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180609222134/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180609222134/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180609222134/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180609222134/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180609222134/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180609222134im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180609222134/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180609222134/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180609222134js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180609222134js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 22:21:34 Jun 09, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:55:30 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 67.411 (3)
  esindex: 0.012
  captures_list: 94.47
  CDXLines.iter: 19.591 (3)
  PetaboxLoader3.datanode: 54.66 (4)
  exclusion.robots: 0.272
  exclusion.robots.policy: 0.254
  RedisCDXSource: 1.727
  PetaboxLoader3.resolve: 155.762
  load_resource: 191.521
-->